Status:
COMPLETED
Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders
Lead Sponsor:
Materia Medica Holding
Conditions:
Chronic Cerebral Ischemia
Eligibility:
All Genders
18-90 years
Brief Summary
An open-label, prospective, observational, multicenter study. The study enrolls adult outpatients with CCI from 8 federal districts of the Russian Federation.
Detailed Description
Medical data (demographic and clinical characteristics - diagnosis, MoCA test results) are collected from patients to whom Divaza is prescribed to be taken according to the following regimen: 2 tablet...
Eligibility Criteria
Inclusion
- Patients of either gender aged 18+ years.
- Diagnosis of chronic cerebral ischemia (CCI) based on the clinical history of underlying vascular disease(atherosclerosis and/or arterial hypertension) and neurological signs.
- Unchanged basic therapy of CCI and underlying vascular disease for a previous 3 month.
- Signed informed consent form.
Exclusion
- Other neurological diseases.
- Any known allergy to/intolerance of any constituent of the medication.
- Pregnancy, breast-feeding.
- Participation in other clinical trials for 3 months prior to enrollment in this study.
- The patient is related to the research personnel of the investigative sites that are directly involved in the study, or is the immediate relative of the investigator, or the employee of OOO NPF Materia Medica Holding.
Key Trial Info
Start Date :
October 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
2583 Patients enrolled
Trial Details
Trial ID
NCT04370028
Start Date
October 1 2016
End Date
January 1 2017
Last Update
March 10 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.